Anthropic acquires Coefficient Bio for $400M

$400M is a lot of money to spend on a vertical you could've just... prompted your way into. That's my first reaction.

Honestly, though, this makes sense if you squint at it right. Anthropic's been trying to crack life sciences since the Claude Life Sciences launch in October, and domain-specific models need domain-specific data. You can't fine-tune your way into FDA-grade reasoning without real scientific expertise in-house.

Here's the thing — this is Anthropic signaling that "general-purpose" is a phase, not a destination. Every major player is picking verticals now. Medicine, law, finance. The foundation model era is quietly becoming the vertical model era.

For us as a small dev shop? Probably doesn't change our day-to-day. We're not building drug discovery pipelines. But watch for the Claude APIs to start reflecting this — specialized endpoints, domain-locked pricing tiers, compliance guardrails baked in.

The real tell will be whether Anthropic follows this with legal or finance acquisitions. If they do, the "Claude is neutral infrastructure" story is officially dead.